In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.
A new opinion analysis argues that TrumpRx has a critical blind spot that could reshape patient access, warning that while the policy emphasizes cost containment, it may overlook downstream impacts on coverage, innovation incentives, and equitable access for complex and specialty therapies.
In regulatory news, the FDA has issued a national priority voucher connected to Tecvayli for the treatment of relapsed or refractory multiple myeloma. The designation underscores the agency’s interest in accelerating access to therapies addressing high unmet need in oncology and rare cancers.
Meanwhile, Sobi has reached a $1.5 billion definitive agreement to acquire Arthrosi Therapeutics, expanding its portfolio with a late-stage gout treatment. The deal strengthens Sobi’s position in inflammation and rare disease while signaling continued M&A interest in specialty metabolic conditions.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
